Moderna, Inc. — Director's Dealing 2020

Jul 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-07-07

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-07	Common Stock	M	22936	$12.21	Acquired	22936	Direct
2020-07-07	Common Stock	M	24121	$19.15	Acquired	47057	Direct
2020-07-07	Common Stock	M	15631	$19.15	Acquired	62688	Direct
2020-07-07	Common Stock	S	23787	$58.21	Disposed	38901	Direct
2020-07-07	Common Stock	S	17393	$58.97	Disposed	21508	Direct
2020-07-07	Common Stock	S	7739	$60.05	Disposed	13769	Direct
2020-07-07	Common Stock	S	13769	$60.98	Disposed	0	Direct
2020-07-08	Common Stock	M	10000	$20.93	Acquired	10000	Direct
2020-07-08	Common Stock	M	10000	$19.15	Acquired	20000	Direct
2020-07-08	Common Stock	S	3238	$60.27	Disposed	16762	Direct
2020-07-08	Common Stock	S	15619	$61.35	Disposed	1143	Direct
2020-07-08	Common Stock	S	1143	$62.16	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-07	Stock Option (Right to Buy)	$12.21	M	22936	Disposed	2027-10-03	Common Stock (22936)	Direct
2020-07-07	Stock Option (Right to Buy)	$19.15	M	24121	Disposed	2026-08-10	Common Stock (24121)	Direct
2020-07-07	Stock Option (Right to Buy)	$19.15	M	15631	Disposed	2026-08-10	Common Stock (15631)	Direct
2020-07-08	Stock Option (Right to Buy)	$20.93	M	10000	Disposed	2029-03-08	Common Stock (10000)	Direct
2020-07-08	Stock Option (Right to Buy)	$19.15	M	10000	Disposed	2026-08-10	Common Stock (10000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.57 to $58.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.58 to $59.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.61 to $60.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.63 to $61.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: This option is fully vested and exercisable.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.77 to $60.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.80 to $61.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.94 to $62.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F10: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).